Potentiation of the inhibitory effect of growth hormone-releasing hormone antagonists on PC-3 human prostate cancer by bombesin antagonists indicative of interference with both IGF and EGF pathways

This publication has 27 references indexed in Scilit:

• Antagonistic Analogs of Growth Hormone-releasing Hormone: New Potential Antitumor Agents
  Published by Elsevier ,1999
• Bombesin/gastrin-releasing peptide antagonists RC-3095 and RC-3940-II inhibit tumor growth and decrease the levels and mRNA expression of epidermal growth factor receptors in H-69 small cell lung carcinoma
  Cancer, 1998
• Insulin-like growth factor 1 and prostate cancer risk: a population-based, case-control study.
  JNCI Journal of the National Cancer Institute, 1998
• Epidermal growth factor receptor activation in androgen-independent but not androgen-stimulated growth of human prostatic carcinoma cells
  British Journal of Cancer, 1998
• In vitro regulation of pericellular proteolysis in prostatic tumor cells treated with bombesin
  International Journal of Cancer, 1998
• Plasma Insulin-Like Growth Factor-I and Prostate Cancer Risk: A Prospective Study
  Science, 1998
• Peptide growth factors and prostate cancer: new models, new opportunities.
  Cancer and Metastasis Reviews, 1998
• Inhibition of growth of androgen-independent DU-145 prostate cancer in vivo by luteinising hormone-releasing hormone antagonist cetrorelix and bombesin antagonists RC-3940-II and RC-3950-II
  European Journal Of Cancer, 1997
• Effect of somatostatin analog RC‐160 and bombesin/gastrin releasing peptide antagonist RC‐3095 on growth of PC‐3 human prostate‐cancer xenografts in nude mice
  International Journal of Cancer, 1993
• Differential Effects of Peptide Hormones Bombesin, Vasoactive Intestinal Polypeptide and Somatostatin Analog RC-160 on the Invasive Capacity of Human Prostatic Carcinoma Cells
  Journal of Urology, 1993